Kymera Therapeutics KYMR
NASDAQ KYMR
$117.45 +0.17 (+0.14%)
As of: Sep 4, 2026 · 3:59 PM EDT

Kymera Therapeutics (KYMR) Net Income Growth (3y) (2022 - 2026)

Analysis

Kymera Therapeutics (KYMR) Net Income Growth (3y) (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 6.30%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 10.23%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 116.82%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 17.25%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 37.89%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 37.44%
8 Royalty Pharma 28.45 Bn 27.61 Bn - -38.56%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 62.15%
10 Kymera Therapeutics 11.52 Bn 10.83 Bn - -20.34%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -20.34%
Mar 31, 2026 -22.89%
Dec 31, 2025 -36.31%
Sep 30, 2025 -27.28%
Jun 30, 2025 -27.50%
Mar 31, 2025 -26.30%
Dec 31, 2024 -33.40%
Sep 30, 2024 -35.98%
Jun 30, 2024 -27.23%
Mar 31, 2024 -63.72%
Dec 31, 2023 -14.77%
Sep 30, 2023 -92.16%
Jun 30, 2023 -45.10%
Mar 31, 2023 -59.04%
Dec 31, 2022 -48.51%
Sep 30, 2022 -55.85%